BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY)'s Avastin Shows Mixed Results in Glioblastoma


11/19/2012 7:17:37 AM

A new study of Roche's Avastin has shown the drug can extend progression-free survival (PFS) by more than four months when added onto standard therapy for an aggressive form of brain cancer. The AVAglio trial found that adding Avastin (bevacizumab) to radiation and temozolomide chemotherapy reduced the risk of cancer progression by 36 per cent, extending PFS from 6.2 months with placebo to 10.6 months, in newly-diagnosed glioblastoma patients. Roche's drug also had significant benefits on health-related quality of life measures - such as allowing patients to live independently for longer - and reduced use of concomitant therapies such as corticosteroids. Avastin is already approved in Europe to treat colorectal cancer, breast cancer, lung cancer, kidney cancer and ovarian cancer, and is available in the US for colorectal cancer, non-small cell lung cancer and kidney cancer and also as a monotherapy for glioblastoma that has progressed despite prior treatment. "People with newly diagnosed glioblastoma have few treatment options and need new medicines," said Hal Barron, Novartis' chief medical officer and head of global product development, adding the plans to discuss the results with regulatory authorities.


Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES